Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy.

Trial Profile

Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Fludarabine; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
    • 16 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 22 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top